Brief: Neumora Therapeutics Announces NMRA-266 IND Clearance, Initiation Of Phase 1 Clinical Study
27/11/2023 12:17
Nov 27 (Reuters) - Neumora Therapeutics Inc NMRA.O :
* NEUMORA THERAPEUTICS ANNOUNCES NMRA-266 IND CLEARANCE AND
INITIATION OF PHASE 1 CLINICAL STUDY
Source text for Eikon: ID:nGNX9DHWHW
Further company coverage: NMRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neumora Therapeutics
See all newsNeumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex